This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Boots Bite and Sting Relief Antihistamine

OTC
Read time: 1 mins
Last updated: 02 Jan 2024
...
 

Summary of product characteristics


1. Name of the medicinal product

Bite and Sting Relief Antihistamine Cream or Boots Bite & Sting Relief 2 Years Plus Antihistamine Cream


2. Qualitative and quantitative composition

Active Ingredient

% quantity

Mepyramine maleate, Ph Eur.

2.0% w/w

Excipients of Known Effect

% quantity

Cetostearyl alcohol

8 % w/w

Lanolin anhydrous

1 % w/w

For more information see section 6.1


3. Pharmaceutical form

Cream.


4.1. Therapeutic indications

P:

For the symptomatic relief of insect bites and stings and nettle rash.

GSL:

For the symptomatic relief of insect bites and stings and nettle stings.


4.2. Posology and method of administration

P: For adults, children and the elderly: Rub gently on to the affected area sparingly two or three times each day for up to three days.

GSL: For adults, elderly and children 2 years of age and over: Rub gently on to the affected area sparingly two or three times each day for up to three days.

For topical application to the skin.


4.3. Contraindications

Hypersensitivity to any of the ingredients or other antihistamines.

Should not be applied to acute vesicular and exudative dermatoses or eczema.


4.4. Special warnings and precautions for use

P & GSL:

Do not apply to broken skin or eczema.

Not to be applied to large areas of skin.

If rash develops or gets worse stop using the product.

For external use only.

Keep all medicines out of the reach of children.

If symptoms do not go away, talk to your doctor.

In addition GSL:

Do not apply to sunburnt skin.

This medicine contains lanolin and cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis)


4.5. Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions expected.


4.6. Fertility, pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established. In view of the potential for systemic absorption through the skin, the product should not be used during these periods unless under medical supervision.


4.7. Effects on ability to drive and use machines

No adverse effects known.


4.8. Undesirable effects

Occasional local hypersensitivity reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.


4.9. Overdose

In cases of excessive application to the skin, sufficient absorption may occur to give rise to systemic adverse effects. Treatment should be symptomatic.


5.1. Pharmacodynamic properties

Mepyramine maleate is an H1 receptor antagonist (antihistamine) of the ethylene diamine type. It diminishes or abolishes the effects of histamine in the body by competitive reversible blockade of histamine receptor sites on tissues.


5.2. Pharmacokinetic properties

Mepyramine maleate is readily absorbed through the skin, metabolised in the liver and excreted, mainly as metabolites in the urine.


5.3. Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.


6.1. List of excipients

White soft paraffin BP

Liquid paraffin Ph Eur

Anhydrous lanolin EP

Arlacel 83 HSE

Cetomacrogol 1000 BP

Cetostearyl alcohol Ph Eur

CitricacidmonohydratePhEur

Sodium citrate Ph Eur

Purified water Ph Eur


6.2. Incompatibilities

None known.


6.3. Shelf life

24 months.


6.4. Special precautions for storage

Do not store above 25°C.


6.5. Nature and contents of container

A collapsible internally lacquered aluminium tube with membrane seal fitted with a high density polyethylene cap.

Pack size

P: 25gm, 30gm.

GSL: 20g


6.6. Special precautions for disposal and other handling

Not applicable.


7. Marketing authorisation holder

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA


8. Marketing authorisation number(s)

PL 00014/0440


9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 28 September 1993

Date of last renewal: 12 November 2003


10. Date of revision of the text

17th November 2023

4.1 Therapeutic indications

P:

For the symptomatic relief of insect bites and stings and nettle rash.

GSL:

For the symptomatic relief of insect bites and stings and nettle stings.

4.2 Posology and method of administration

P: For adults, children and the elderly: Rub gently on to the affected area sparingly two or three times each day for up to three days.

GSL: For adults, elderly and children 2 years of age and over: Rub gently on to the affected area sparingly two or three times each day for up to three days.

For topical application to the skin.

4.3 Contraindications

Hypersensitivity to any of the ingredients or other antihistamines.

Should not be applied to acute vesicular and exudative dermatoses or eczema.

4.4 Special warnings and precautions for use

P & GSL:

Do not apply to broken skin or eczema.

Not to be applied to large areas of skin.

If rash develops or gets worse stop using the product.

For external use only.

Keep all medicines out of the reach of children.

If symptoms do not go away, talk to your doctor.

In addition GSL:

Do not apply to sunburnt skin.

This medicine contains lanolin and cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis)

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions expected.

4.6 Fertility, pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established. In view of the potential for systemic absorption through the skin, the product should not be used during these periods unless under medical supervision.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

Occasional local hypersensitivity reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store.

Drug section

A close up image of a microscope
Clinical trial
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.

2 mins
Clinical trial
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

To demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess long term efficacy, safety and tolerability of secukinumab.

4 min
Clinical trial
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2)

This study will evaluate the effects of an experimental (being tested) study drug called apremilast.

2 min
Journals
Journal
Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions

Objective: We sought to evaluate the efficacy and patient satisfaction of the deroofing technique for recurrent Hurley I (mild) or II (moderate) graded HS lesions at fixed locations.

1 mins
Journal
Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management

<p>The recognition of the central role of interleukin 17A (IL-17A) in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes.</p>

1 min
Journal
Morbidity in patients with hidradenitis suppurativa

Objectives: To measure the impairment of life quality in patients with HS.

1 min
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).